Geller NL - Search Results

1

Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy.

Geller NL, Sternberg CN, Penenberg D, Scher H, Yagoda A. Geller NL, et al. Cancer. 1991 Mar 15;67(6):1525-31. doi: 10.1002/1097-0142(19910315)67:6<1525::aid-cncr2820670611>3.0.co;2-8. Cancer. 1991. PMID: 2001540

2

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.

Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, et al. Sternberg CN, et al. Cancer. 1989 Dec 15;64(12):2448-58. doi: 10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7. Cancer. 1989. PMID: 2819654

3

Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer.

Scher HI, Shank B, Chapman R, Geller N, Pinsky C, Gralla R, Kelsen D, Bosl G, Golbey R, Petroni G, et al. Scher HI, et al. Cancer Res. 1988 Mar 15;48(6):1663-70. Cancer Res. 1988. PMID: 2830968 Clinical Trial.

4

Gallium nitrate in prostatic cancer: evaluation of antitumor activity and effects on bone turnover.

Scher HI, Curley T, Geller N, Dershaw D, Chan E, Nisselbaum J, Alcock N, Hollander P, Yagoda A. Scher HI, et al. Cancer Treat Rep. 1987 Oct;71(10):887-93. Cancer Treat Rep. 1987. PMID: 3308078 Clinical Trial.

5

Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy.

Petrylak DP, Scher HI, Li Z, Myers CE, Geller NL. Petrylak DP, et al. Among authors: geller nl. Cancer. 1992 Dec 15;70(12):2870-8. doi: 10.1002/1097-0142(19921215)70:12<2870::aid-cncr2820701225>3.0.co;2-f. Cancer. 1992. PMID: 1451069

6

Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors.

Motzer RJ, Cooper K, Geller NL, Pfister DG, Lin SY, Bajorin D, Scher HI, Herr H, Fair W, Morse M, et al. Motzer RJ, et al. Among authors: geller nl. Cancer. 1990 Jun 1;65(11):2465-70. doi: 10.1002/1097-0142(19900601)65:11<2465::aid-cncr2820651112>3.0.co;2-7. Cancer. 1990. PMID: 1692505

7

Advanced seminoma: the role of chemotherapy and adjunctive surgery.

Motzer RJ, Bosl GJ, Geller NL, Penenberg D, Yagoda A, Golbey R, Whitmore WF Jr, Fair WR, Sogani P, Herr H, et al. Motzer RJ, et al. Among authors: geller nl. Ann Intern Med. 1988 Apr;108(4):513-8. doi: 10.7326/0003-4819-108-4-513. Ann Intern Med. 1988. PMID: 2450500

8

A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.

Bosl GJ, Geller NL, Bajorin D, Leitner SP, Yagoda A, Golbey RB, Scher H, Vogelzang NJ, Auman J, Carey R, et al. Bosl GJ, et al. Among authors: geller nl. J Clin Oncol. 1988 Aug;6(8):1231-8. doi: 10.1200/JCO.1988.6.8.1231. J Clin Oncol. 1988. PMID: 2457657 Clinical Trial.

9

Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC.

Scher HI, Geller NL, Curley T, Tao Y. Scher HI, et al. Among authors: geller nl. J Clin Oncol. 1993 Mar;11(3):400-7. doi: 10.1200/JCO.1993.11.3.400. J Clin Oncol. 1993. PMID: 8445414

10

Chemotherapeutic management of invasive bladder carcinoma.

Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Geller N, et al. Sternberg CN, et al. Eur Urol. 1988;14 Suppl 1:19-20. doi: 10.1159/000473033. Eur Urol. 1988. PMID: 3053199 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

268 results

Search Page

Filters